Osteoporose

Andreas Kurth; Michael Rauschmann; Peyman Hadji

doi:10.1055/a-0968-7097

Die Wirbelsäule 2020; 04(03): 219-238
DOI: 10.1055/a-0968-7097

CME-Fortbildung

Osteoporose

Moderne Diagnostik und Therapie – Empfehlungen für den AlltagOsteoporosisModern Diagnostics and Therapy – Recommendations for Everyday Life

Andreas Kurth

,

Michael Rauschmann

,

Peyman Hadji

Verantwortlicher Herausgeber dieser Rubrik: Wissenschaftlich verantwortlich gemäß Zertifizierungsbestimmungen für diesen Beitrag ist Prof. Dr. med. Andreas Kurth, Koblenz.

Abstract

Zusammenfassung

Etwa 50 % der Frauen und 20 % der Mann ab 50 Jahren erleiden eine osteoporosebedingte Fraktur. Knochenbrüche im Alter sind die Ursache für ein erhöhtes Risiko für weitere Frakturen, eine erhöhte Sterblichkeit, zusätzliche Erkrankungen und Einschränkung der körperlichen Funktionen und dadurch reduzierte Lebensqualität und Verlust der Unabhängigkeit im täglichen Leben. Das übergeordnete Ziel der Diagnostik und Behandlung von Osteoporosepatienten besteht darin, Frakturen zu verhindern.

Abstract

Approximately one out of two women and 20 % of all men aged 50 years and more will suffer from an osteoporosis-related fracture. Broken bones in old age cause an increased risk of further fractures, an increased mortality, additional illnesses and reduced physical functions and thereby restriction of the quality of life and the loss of independence in daily life. More than half the patients suffer a subsequent fracture after the first one, which results in further hospital stays and operations. The primary goal of diagnosis and treatment of osteoporosis patients is to prevent the occurrence of fractures.

Schlüsselwörter

Knochenqualität - Knochendichte - Lebensqualität - Fraktur - Knochenbruch

Keywords

fracture - broken bone - quality of life - bone density - bone quality

Volltext

Referenzen

Literatur
1 Consensus Development Conference. Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993; 94: 646-650
2 Kanis JA. (on behalf of the) World Health Organization Scientific Group. Assessment of osteoporosis at the primary health-care level. Technical Report. World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK. 2007: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843. Geneva: WHO; 1994
3 Hernlund E, Svedbom A, Ivergard M. et al. IOF Bericht 2013. Osteoporosis in the EU: medical management, epidemionology and economic burden. Arch Osteoporosis 2013; 8: 136
4 Elliot-Gibson V, Bogoch ER, Jamal SA. et al. Practice patterns in the diagnosis and treatment of osteoporosis after a fragilityfracture: a systematic review. Osteoporos Int 2004; 15: 767-778
5 Kanis JA, Johnell O, Oden A. et al. Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 2000; 11: 669-674
6 Hendrickx G, Boudin E, Van Hul W. A look behind the scenes: the risk and pathogenesis of primary osteoporosis. Nat Rev Rheumatol 2015; 11: 462-474
7 Bishop N, Arundel P, Clark E. et al. International Society of Clinical DensitometryFracture prediction and the definition of osteoporosis in children and adolescents: the ISCD 2013 Pediatric Official Positions. J Clin Densitom 2014; 17: 275-280
8 Zebaze RM, Ghasem-Zadeh A, Bohte A. et al. Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet 2010; 375: 1729-1736
9 Ahlborg HG, Johnell O, Turner CH. et al. Bone loss and bone size after menopause. N Engl J Med 2003; 349: 327-334
10 Leslie WD, Lix LM, Majumdar SR. et al. Total hip bone area affects fracture prediction with FRAX in Canadian white women. J Clin Endocrinol Metab 2017; 102: 4242-4249
11 Chang KP, Center JR, Nguyen TV. et al. Incidenceof hip and other osteoporotic fractures in elderly men and women: Dubbo Osteoporosis Epidemiology Study. J Bone Miner Res 2004; 19: 532-536
12 Jiang HX, Majumdar SR, Dick DA. et al. Development and initial validation of a risk score for predicting in-hospital and 1-year mortality in patientswith hip fractures. J Bone Miner Res 2005; 20: 494-500
13 Khosla S. Update in male osteoporosis. J Clin Endocrinol Metab 2010; 95: 3-10
14 Fitzpatrick LA. Secondary causes of osteoporosis. Mayo Clin Proc 2002; 77: 453-468
15 Lambert JK, Zaidi M, Mechanick JI. Male osteoporosis: epidemiology and the pathogenesis of aging bones. Curr Osteoporos Rep 2011; 9: 229-236
16 Painter SE, Kleerekoper M, Camacho PM. Secondary osteoporosis: a review of the recent evidence. Endocr Pract 2006; 12: 436-445
17 Hofbauer LC, Gori F, Riggs BL. et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999; 140: 4382-4389
18 Angeli A, Guglielmi G, Dovio A. et al. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone 2006; 39: 253-259
19 de Liefde II, van der Klift M, de Laet CE. et al. Bone mineral density and fracture risk in type–2 diabetes mellitus: the Rotterdam Study. Osteoporos Int 2005; 16: 1713-1720
20 Shepherd JA, Schousboe JT, Broy SB. et al. Executive summary of the 2015 ISCD Position Development Conference on Advanced Measures from DXA and QCT: fracture prediction beyond BMD. J Clin Densitom 2015; 18: 274-286
21 Genant HK, Wu CY, van Kuijk C. et al. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993; 8: 1137-1148
22 Briot K, Cortet B, Thomas T. et al. 2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis. Joint Bone Spine 2012; 79: 304-313
23 Harvey NC, Glüer CC, Binkley N. et al. Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice. Bone 2015; 78: 216-224
24 Schousboe JT, Shepherd JA, Bilezikian JP. et al. Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry. J Clin Densitom 2013; 16: 455-466
25 Nishiyama KK, Shane E. Clinical imaging of bone microarchitecture with HR-pQCT. Curr Osteoporos Rep 2013; 11: 147-155
26 Dachverband Osteologie e.V. – DVO. Prophylaxe, Diagnostik und Therapie der OSTEOPOROSE bei postmenopausalen Frauen und bei Männern. Leitlinie des Dachverbands der Deutschsprachigen Wissenschaftlichen Osteologischen Gesellschaften. Im Internet (Stand: 18.04.2020): https://www.dv-osteologie.org/uploads/Leitlinie%202017/Finale%20Version%20Leitlinie%20Osteoporose%202017_end.pdf
27 Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002; 359: 1929-1936
28 Kanis JA, Johnell O, Oden A. et al. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 2001; 12: 989-995
29 Klotzbuecher CM, Ross PD, Landsman PB. et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000; 15: 721-739
30 Weinstein RS. Clinical practice: Glukokortikoid-induced bone disease. N Engl J Med 2011; 365: 62-70
31 Rizzoli R, Stevenson JC, Bauer JM. et al. ESCEO Task Force. The role of dietary protein and vitamin D in maintaining musculoskeletal health in postmenopausal women: a consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Maturitas 2014; 79: 122-132
32 Weaver CM, Alexander DD, Boushey CJ. et al. Calcium plus vitamin D supplementation and risk of fractures: an updated meta-analysis from the National Osteoporosis Foundation. Osteoporos Int 2016; 27: 367-376
33 Rizzoli R. Nutritional aspects of bone health. Best Pract Res Clin Endocrinol Metab 2014; 28: 795-808
34 Black DM, Cummings SR, Karpf DB. et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348: 1535-1541
35 Mellstrom DD, Sorensen OH, Goemaere S. et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004; 75: 462-468
36 Delmas PD, Recker RR, Chesnut 3rd CH. et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004; 15: 792-798
37 Black DM, Reid IR, Boonen S. et al. The effect of 3 versus 6 years of zoledronic acid treatment in osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2012; 27: 243-254
38 Resch H, Trubrich A, Kocijan R. et al. Denosumab – the RANKL-antibody as an example of the biotechnological development. Osteologie 2011; 20: 203-210
39 Pinkerton JV, Thomas S. Use of SERMs for treatment in postmenopausal women. J Steroid Biochem Mol Biol 2014; 142: 142-154
40 S3-Leitlinie Antiresorptiva-asoziierte Kiefernekrosen (AR-ONJ). AWMF-Register-Nr. 007-091. www.awmf.org
41 Rizzoli R, Reginster JY, Boonen S. et al. Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int 2011; 89: 91-104
42 Adler RA, El-Hajj Fuleihan G, Bauer DC. et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2016; 31: 16-35
43 Shane E, Burr D, Ebeling PR. et al. American Society for Bone and Mineral Research Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010; 25: 2267-2294
44 Kendler DL, Marin F, Cristiano AF. et al. Effects of Teriparatide and Risedronate on New Fractures in Postmenopausal Women with Severe Osteoporosis (VERO): A Multicenter, Double-blind, Double-dummy, Randomized Controlled Trial. Lancet 2018; 391: 230-240
45 Tian X, Jee WS, Li X. et al. Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb immobilization rat model. Bone 2011; 48: 197-201
46 Cosman F, Crittenden DB, Grauer A. Romosozumab treatment in post menopausal osteoporosis. N Engl J Med 2017; 376: 396-397
47 Saag KG, Petersen J, Brandi ML. et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 2017; 377: 1417-1427
48 Brumsen C, Hamdy NA, Papapoulos SE. Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine (Baltimore) 1997; 76: 266-283
49 International Osteoporosis Foundation. Capture the fracture: fracture liason services. Im Internet (Stand: 18.04.2020): https://capturethefracture.org/sites/default/files/Osteoporosis%20NZ%20FLS%20Resource%20Pack.pdf